Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India

Executive Summary

Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.

You may also be interested in...



Strides Plans Re-Entry On Injectables

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.

Strides Plans Injectables Re-entry As Mylan Non-Compete Nears End

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.  

Korea IND Filing Moves Alteogen's Eylea Biosimilar Forward

South Korean biotech Alteogen is progressing the development of its Eylea biosimilar both at home and abroad, with the hope of becoming a global first mover with its version in wet AMD, backed by formulation and manufacturing patents.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel